Pituitary gland: Can prolactinomas be cured medically?

Nature Reviews Endocrinology

Volumn 6, Issue 4, 2010, Pages 186-188

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN;

APOPTOSIS; CELL DEATH; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; LONG TERM CARE; META ANALYSIS; MICROADENOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT DURATION; TUMOR RECURRENCE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; DOPAMINE AGONISTS; ERGOLINES; HUMANS; HYPERPROLACTINEMIA; META-ANALYSIS AS TOPIC; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTINOMA; RECURRENCE; WITHHOLDING TREATMENT;

EID: 77950219832     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.278     Document Type: Short Survey

References (10)

1. Dekkers, O. M. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. doi:10.1210/jc.2009-1238.
2. Ben-Jonathan, n. & Hnasko, R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 22, 724-763 (2001).
3. Kontogeorgos, G. et al. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol. 111, 46-52 (2006).
4. Landolt, A. M. & Osterwalder, v. Perivascular fibrosis in prolac tinomas: is it increased by bromocrip tine? J. Clin. Endocrinol. Metab. 58, 1179-1183 (1984).
5. stefaneanu, L. et al. effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr. Pathol. 11, 341-352 (2000).
6. esiri, M. M., Bevan, J. s., Burke, C. w. & Adams, C. B. effect of bromocrip tine treatment on the fibrous tissue content of prolactinsecreting and nonfunctioning macroadenomas of the pituitary gland. J. Clin. Endocrinol. Metab. 63, 383-388 (1986).
7. Gillam, M. P., Molitch, M. e., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (2006).
8. Colao, A. et al. Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. 67, 426-433 (2007).
9. Colao, A. et al. withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023-2033 (2003).
10. Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428-2436 (2009).